Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3969 |
Name | papillary thyroid carcinoma |
Definition | A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer and arises from the follicular cells of the thyroid gland. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer carcinoma adenocarcinoma papillary adenocarcinoma papillary thyroid carcinoma |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated high-grade thyroid carcinoma papillary thyroid carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RET rearrange | Sorafenib | papillary thyroid carcinoma | sensitive | detail... |
RET rearrange | Ponatinib | papillary thyroid carcinoma | sensitive | detail... |
PIK3CA E542K | MK2206 | papillary thyroid carcinoma | sensitive | detail... |
PIK3CA E542K | MK2206 + Temsirolimus | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E | RO5126766 | papillary thyroid carcinoma | sensitive | detail... |
TP53 wild-type | Alrizomadlin | papillary thyroid carcinoma | sensitive | detail... |
RET fusion | Selpercatinib | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | papillary thyroid carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib | papillary thyroid carcinoma | sensitive | detail... |
BRAF K601E | Denosumab + Sorafenib | papillary thyroid carcinoma | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | papillary thyroid carcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E PIK3CA W11C PIK3CA E542K | Dasatinib + Trametinib | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E NRAS Q61K | Vemurafenib | papillary thyroid carcinoma | predicted - resistant | detail... |
BRAF V600E | Binimetinib + Encorafenib | papillary thyroid carcinoma | sensitive | detail... |
BRAF V600E | Ravoxertinib | papillary thyroid carcinoma | sensitive | detail... |
BRAF del exon2-8 BRAF V600E | Binimetinib + PF-07799933 | papillary thyroid carcinoma | predicted - sensitive | detail... |
BRAF V600E | AZD1208 + Vemurafenib | papillary thyroid carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT01534897 | Phase I | Dabrafenib | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | Completed | USA | 0 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 0 |
NCT01709292 | Phase II | Vemurafenib | Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT01723202 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer | Unknown status | USA | 0 |
NCT02145143 | Phase 0 | Vemurafenib | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | Completed | USA | 0 |
NCT02211222 | Phase I | Lenvatinib | An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | Approved for marketing | USA | 0 |
NCT02702388 | Phase II | Lenvatinib | Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Completed | USA | SWE | ROU | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 2 |
NCT02973997 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03002623 | Phase II | CUDC-907 | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | Terminated | USA | 0 |
NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
NCT03244956 | Phase II | Trametinib Dabrafenib + Trametinib | Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) | Unknown status | FRA | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03469011 | Phase I | Imatinib | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | Recruiting | CAN | 0 |
NCT03732495 | Phase II | Denosumab + Lenvatinib | Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) | Unknown status | FRA | 0 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
NCT03914300 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04321954 | Phase II | Lenvatinib | Lenvatinib in Locally Advanced Invasive Thyroid Cancer | Recruiting | USA | 0 |
NCT04462471 | Phase I | Copanlisib + Vemurafenib | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | Completed | USA | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Active, not recruiting | USA | ISR | ESP | 0 |
NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Active, not recruiting | USA | AUS | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05660954 | Phase II | Cabozantinib | Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (CABOTHYROID) | Active, not recruiting | ESP | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT06440850 | Phase II | Cobimetinib + Vemurafenib | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | Recruiting | USA | 0 |
NCT06475989 | Phase III | Dabrafenib + Trametinib Cabozantinib | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Recruiting | USA | 0 |